|Assessment Status||Assessment process complete|
|Indication||For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.|
|Rapid review commissioned||01/11/2021|
|Rapid review completed||10/12/2021|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that filgotinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations May 2022.